76 research outputs found

    ABOUT THE SMARANDACHE SQUARES COMPLEMENTARY FUNCTION

    Get PDF
    A discussion about the Smarandache Squares Complementary Function

    Cardiovascular function and ballistocardiogram: a relationship interpreted via mathematical modeling

    Get PDF
    Objective: to develop quantitative methods for the clinical interpretation of the ballistocardiogram (BCG). Methods: a closed-loop mathematical model of the cardiovascular system is proposed to theoretically simulate the mechanisms generating the BCG signal, which is then compared with the signal acquired via accelerometry on a suspended bed. Results: simulated arterial pressure waveforms and ventricular functions are in good qualitative and quantitative agreement with those reported in the clinical literature. Simulated BCG signals exhibit the typical I, J, K, L, M and N peaks and show good qualitative and quantitative agreement with experimental measurements. Simulated BCG signals associated with reduced contractility and increased stiffness of the left ventricle exhibit different changes that are characteristic of the specific pathological condition. Conclusion: the proposed closed-loop model captures the predominant features of BCG signals and can predict pathological changes on the basis of fundamental mechanisms in cardiovascular physiology. Significance: this work provides a quantitative framework for the clinical interpretation of BCG signals and the optimization of BCG sensing devices. The present study considers an average human body and can potentially be extended to include variability among individuals

    Clinical Phenotype of Bernard Soulier Syndrome Case Resulting from Compound Heterozygous Inheritance

    Get PDF
    Background: Bernard Soulier Syndrome (BSS) is a rare, autosomal recessive inheritance disorder of platelet function. Estimated to affect one per one million, there are currently only 200 cases reported worldwide presenting more commonly in families with parental consanguinity. This syndrome occurs when there is a genetic defect in the subunits (GPIb-alpha, GPIB-beta, and GP9) that form the GPIb-IX-V complex. The result is inadequate binding to von Willebrand factor. The clotting cascade is, therefore, unable to begin, causing symptoms of excessive and prolonged bleeding. Objectives: We report a case with multiple episodes of exaggerated bleeding and easy bruising. Methods: We analyzed complete blood count, coagulation studies, platelet aggregation assays, platelet glycoprotein expression by flow cytometry, as well as screened both patient and parents for relevant genes responsible for BSS. Results: 14-month-old Caucasian male born at 38w3d gestational age, non-consanguineous parents with multiple episodes of exaggerated bleeding and easy bruising from minor injuries. His symptoms started early in life with excessive bleeding after circumcision. No history of intramuscular, joint, or intracranial bleeding. Complete blood counts showed macrothrombocytopenia (98 X109 /L MPV 12.3 fl) no leukocyte inclusion bodies on peripheral smear. Coagulation tests (prothrombin time, activated partial thromboplastin time, vWF antigen, and vW-Ristocetin cofactor activity, platelet function assay) were normal. Platelet glycoprotein expression by flow cytometry revealed significantly reduced binding of monoclonal antibodies to platelet GPIb and normal GPIIb/IIIa. Comprehensive platelet disorder panel revealed two clinically significant variants missense mutations in the GP9 gene (P.Cys135 Tyr and P.Asn61Ser) These variants were on opposite alleles and results were consistent with the diagnosis of Bernard Soulier syndrome (BSS). The mother reported heavy menstrual cycles, the father had no significant bleeding symptoms, and both parents had normal platelet counts. Target genetic testing identified these two distinct missense mutations from both Mother and Father of the child. Conclusion: The two rare variants occurring on the gene for GPIX (GP9) increase the number of known genetic defects associated with the manifestation of Bernard Soulier Syndrome

    Building a Data Set over 12 Globally Distributed Sites to Support the Development of Agriculture Monitoring Applications with Sentinel-2

    Get PDF
    Developing better agricultural monitoring capabilities based on Earth Observation data is critical for strengthening food production information and market transparency. The Sentinel-2 mission has the optimal capacity for regional to global agriculture monitoring in terms of resolution (10–20 meter), revisit frequency (five days) and coverage (global). In this context, the European Space Agency launched in 2014 the “Sentinel­2 for Agriculture” project, which aims to prepare the exploitation of Sentinel-2 data for agriculture monitoring through the development of open source processing chains for relevant products. The project generated an unprecedented data set, made of “Sentinel-2 like” time series and in situ data acquired in 2013 over 12 globally distributed sites. Earth Observation time series were mostly built on the SPOT4 (Take 5) data set, which was specifically designed to simulate Sentinel-2. They also included Landsat 8 and RapidEye imagery as complementary data sources. Images were pre-processed to Level 2A and the quality of the resulting time series was assessed. In situ data about cropland, crop type and biophysical variables were shared by site managers, most of them belonging to the “Joint Experiment for Crop Assessment and Monitoring” network. This data set allowed testing and comparing across sites the methodologies that will be at the core of the future “Sentinel­2 for Agriculture” system.Instituto de Clima y AguaFil: Bontemps, Sophie. Université Catholique de Louvain. Earth and Life Institute; BélgicaFil: Arias, Marcela. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Cara, Cosmin. CS Romania S.A.; RumaniaFil: Dedieu, Gérard. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Guzzonato, Eric. CS Systèmes d’Information; FranciaFil: Hagolle, Olivier. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Inglada, Jordi. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Matton, Nicolas. Université Catholique de Louvain. Earth and Life Institute; BélgicaFil: Morin, David. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Popescu, Ramona. CS Romania S.A.; RumaniaFil: Rabaute, Thierry. CS Systèmes d’Information; FranciaFil: Savinaud, Mickael. CS Systèmes d’Information; FranciaFil: Sepulcre, Guadalupe. Université Catholique de Louvain. Earth and Life Institute; BélgicaFil: Valero, Silvia. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Ahmad, Ijaz. Pakistan Space and Upper Atmosphere Research Commission. Space Applications Research Complex. National Agriculture Information Center Directorate; PakistánFil: Bégué, Agnès. Centre de Coopération Internationale en Recherche Agronomique pour le Développerment; FranciaFil: Wu, Bingfang. Chinese Academy of Sciences. Institute of Remote Sensing and Digital Earth; República de ChinaFil: De Abelleyra, Diego. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Clima y Agua; ArgentinaFil: Diarra, Alhousseine. Université Cadi Ayyad. Faculté des Sciences Semlalia; MarruecosFil: Dupuy, Stéphane. Centre de Coopération Internationale en Recherche Agronomique pour le Développerment; FranciaFil: French, Andrew. United States Department of Agriculture. Agricultural Research Service. Arid Land Agricultural Research Center; ArgentinaFil: Akhtar, Ibrar ul Hassan. Pakistan Space and Upper Atmosphere Research Commission. Space Applications Research Complex. National Agriculture Information Center Directorate; PakistánFil: Kussul, Nataliia. National Academy of Sciences of Ukraine. Space Research Institute and State Space Agency of Ukraine; UcraniaFil: Lebourgeois, Valentine. Centre de Coopération Internationale en Recherche Agronomique pour le Développerment; FranciaFil: Le Page, Michel. Université Cadi Ayyad. Faculté des Sciences Semlalia. Laboratoire Mixte International TREMA; Marruecos. Universite de Toulose - Le Mirail. Centre d’Etudes Spatiales de la BIOsphère; FranciaFil: Newby, Terrence. Agricultural Research Council; SudáfricaFil: Savin, Igor. V.V. Dokuchaev Soil Science Institute; RusiaFil: Verón, Santiago Ramón. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Clima y Agua; ArgentinaFil: Koetz, Benjamin. European Space Agency. European Space Research Institute; ItaliaFil: Defourny, Pierre. Université Catholique de Louvain. Earth and Life Institute; Bélgic

    Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    Get PDF
    Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
    corecore